Linked Life Data

11454724

Source:http://linkedlifedata.com/resource/pubmed/id/11454724

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11454724rdf:typepubmed:Citationlld:pubmed
pubmed-article:11454724lifeskim:mentionsumls-concept:C0242643lld:lifeskim
pubmed-article:11454724lifeskim:mentionsumls-concept:C0065180lld:lifeskim
pubmed-article:11454724lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:11454724lifeskim:mentionsumls-concept:C0908935lld:lifeskim
pubmed-article:11454724lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:11454724pubmed:issue8lld:pubmed
pubmed-article:11454724pubmed:dateCreated2001-7-16lld:pubmed
pubmed-article:11454724pubmed:abstractTextThe absorption of many drugs is affected by their interaction with ATP-binding cassette (ABC) transporters. The most extensively studied of these ABC transporters is the proein product of MDR1 (multidrug resistance) that encodes a 170-kDa integral plasma membrane phosphorylated glycoprotein known as P-glycoprotein (P-gp). The purpose of this study was to determine, using two different methods, whether the nonsedating antihistamine loratadine (L) and its active metabolite desloratadine (DL) interact with P-gp. MDR cells presenting human P-gp were incubated with the fluorescent P-gp substrate daunorubicin with or without L, DL, and several positive controls. The IC(50) of loratadine (approximately 11 microM) was approximately 160 times the maximum observed plasma concentration (C(max)) following a dose of 10 mg. The IC(50) of desloratadine (approximately 43 microM) was approximately 880 times the C(max) following a dose of 5 mg. The positive control, cyclosporin A, had an IC(50) of approximately 1 microM. ATP hydrolysis activity was measured in the membrane fraction prepared from MDR cells presenting P-gp, which were exposed to various concentrations of test compounds. Known substrates of P-gp demonstrated clear, repeatable, concentration-dependent increases in ATP hydrolysis activity. L caused an increase in ATPase activity above basal levels. L had a V(max) about 200% basal activity and K(m) of approximately 3 microM for P-gp. In contrast, DL had no significant effect on baseline ATP hydrolysis. L inhibited human P-gp much less than verapamil or cyclosporin A. DL inhibited human P-gp significantly less than L (4 times). DL therefore is not a significant inhibitor of P-gp and should not cause clinical drug interactions with agents that are P-gp substrates.lld:pubmed
pubmed-article:11454724pubmed:languageenglld:pubmed
pubmed-article:11454724pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:citationSubsetIMlld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11454724pubmed:statusMEDLINElld:pubmed
pubmed-article:11454724pubmed:monthAuglld:pubmed
pubmed-article:11454724pubmed:issn0090-9556lld:pubmed
pubmed-article:11454724pubmed:authorpubmed-author:JohnsonW WWWlld:pubmed
pubmed-article:11454724pubmed:authorpubmed-author:WoodS NSNlld:pubmed
pubmed-article:11454724pubmed:authorpubmed-author:ClementR PRPlld:pubmed
pubmed-article:11454724pubmed:authorpubmed-author:CascianoC NCNlld:pubmed
pubmed-article:11454724pubmed:issnTypePrintlld:pubmed
pubmed-article:11454724pubmed:volume29lld:pubmed
pubmed-article:11454724pubmed:ownerNLMlld:pubmed
pubmed-article:11454724pubmed:authorsCompleteYlld:pubmed
pubmed-article:11454724pubmed:pagination1080-3lld:pubmed
pubmed-article:11454724pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:meshHeadingpubmed-meshheading:11454724...lld:pubmed
pubmed-article:11454724pubmed:year2001lld:pubmed
pubmed-article:11454724pubmed:articleTitleEvaluation of the interaction of loratadine and desloratadine with P-glycoprotein.lld:pubmed
pubmed-article:11454724pubmed:affiliationDrug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, 144 Route 94, Lafayette, New Jersey 07848, USA.lld:pubmed
pubmed-article:11454724pubmed:publicationTypeJournal Articlelld:pubmed
literatureCitation:1588_114...literatureCitation:pubmedpubmed-article:11454724lld:drugbank